TaiwanJ Pharmaceuticals Co., Ltd.

6549 · TWO · Healthcare / Biotechnology

6.20TWD-0.03 (-0.48%)

Price History

Full chart

Market Stats

Previous Close6.23

Open6.21

Day Range5.92 – 6.22

52-Week Range6.21 – 9.80

Volume60.51K

Market Cap556.85M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.23

Dividend Yield0.00%

Beta-1.13

50-Day Avg6.87

200-Day Avg7.50

About

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Hung-Chang Yuan
Employees13
HeadquartersNo.2 ShengYi Road, Zhubei, Taiwan, 302058, Taiwan
Websitehttps://www.taiwanj.com

Leadership

Mr. Hung-Chang YuanGM & Director
Dr. Edwin Wu Ph.D.Founder & Honorary Chairman
Mr. Zhi Jie GuoAccounting Supervisor

Financials

Income Statement

Currency: TWD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	61.72M	-	22.06M	15.36M	22.74M	0	0
Growth (%)	-	-	-	-30.38%	+48.11%	-100.00%	-
Cost of Revenue	20.29M	1.41M	0	75.28M	0	1.89M	0
Gross Profit	41.44M	-1.41M	22.06M	-59.92M	22.74M	-1.89M	0
Gross Margin	67.13%	-	100.00%	-390.24%	100.00%	-	-
Operating Expense	48.12M	41.02M	31.78M	36.47M	29.35M	25.07M	25.21M
Operating Income	-6.69M	-42.43M	-9.72M	-96.39M	-6.61M	-26.96M	-25.21M
Operating Margin	-10.84%	-	-44.09%	-627.77%	-29.07%	-	-
EBITDA	21.74M	-41.02M	-9.15M	-15.99M	-1.74M	-20.44M	-22.68M
EBITDA Margin	35.23%	-	-41.47%	-104.15%	-7.64%	-	-
Net Income	-5.08M	-42.46M	-12.42M	-92.47M	-6.05M	-22.34M	-24.34M
Net Income Margin	-8.24%	-	-56.32%	-602.19%	-26.59%	-	-
R&D	26.11M	25.98M	17.73M	12.74M	13.97M	10.31M	10.70M
R&D as % of Total Revenue	42.31%	-	80.39%	82.99%	61.45%	-	-
Interest Expense	23.00K	25.00K	13.00K	10.00K	24.00K	13.00K	52.00K
Interest Expense % of Total Revenue	0.04%	-	0.06%	0.07%	0.11%	-	-

Balance Sheet

Currency: TWD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	159.87M	183.20M	170.33M	79.79M	73.56M	100.77M	77.25M
Total Liabilities	8.21M	7.28M	6.85M	8.19M	6.62M	5.71M	6.33M
Total Equity	151.66M	175.92M	163.48M	71.60M	66.94M	95.05M	70.92M
Cash	58.56M	93.45M	82.88M	60.69M	58.83M	47.61M	67.82M
Total Debt	890.00K	890.00K	331.00K	1.86M	1.17M	472.00K	-
Net Debt	-57.67M	-92.56M	-82.55M	-58.83M	-57.66M	-47.13M	-

Cash Flow

Currency: TWD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	16.86M	-41.28M	-10.05M	-21.07M	-821.00K	-22.62M	-24.17M
Investing Cash Flow	-14.58M	10.87M	38.00K	-557.00K	-351.00K	-37.90M	-
Financing Cash Flow	-1.29M	65.30M	-559.00K	-561.00K	-687.00K	49.30M	-
Capital Expenditure	1.47M	1.43M	0	1.23M	1.44M	0	286.00K
Free Cash Flow	15.39M	-42.71M	-10.05M	-22.30M	-2.26M	-22.62M	-24.46M
FCF to OCF	91.28%	103.46%	100.00%	105.81%	275.52%	100.00%	101.18%

Key Statistics & Ratios

Market Cap556.85M

Enterprise Value482.72M

Trailing P/E0.00

Forward P/E0.00

Price / Sales37.82

Price / Book8.41

EPS-0.23

Book Value0.802

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-20.70M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-24.99%

Return on Assets-16.87%

Shares Outstanding80.12M

Shares Float71.71M

Beta-1.13

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%